Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

Open access

Abstract

Background Garsorasib (D-1553), a highly selective, oral KRAS G12C inhibitor, has shown clinical efficacy in NSCLC and CRC and is under evaluation in pancreatic cancer.Methods Pancreatic cancer patients with KRAS G12C mutation were enroled and received garsorasib 600 mg twice daily treatment in two international, multicenter, open-label phase 1/2 trials (NCT04585035 and NCT05383898) with similar eligibility criteria. Their data were pooled for analyses of efficacy and safety endpoints.Results As of April 30, 2024, 24 KRAS G12C-mutated pancreatic cancer patients were enroled with a median follow-up of 8.9 months (range 1.1-22.9). Among 22 evaluable patients, the confirmed objective response rate (ORR) was 45.5% (95% CI, 24.4 to 67.8) with a median duration of response (DOR) of 6.4 months (95% CI, 4.2 to 16.4). The median progression-free survival (PFS) was 7.6 months (95% CI, 3.3 to 8.5) and the 6-month OS rate was 79.2% (95% CI, 57.0, 90.8). Treatment-related adverse events (TRAEs) occurred in 18 (75.0%) patients, including 6 (25.0%) with grade ≥3 events. No TRAEs led to treatment discontinuation. The safety profile was consistent with previous reports of garsorasib.Conclusion Garsorasib demonstrated encouraging antitumor activity and a tolerable safety profile in patients with KRAS G12C-mutated advanced pancreatic cancer.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41416-025-03286-w

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 20 references

Metadata

Authors
Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., Zhang, J., Xiang, Z., Wang, W., Shi, Z., Zhang, L., Wang, Y., & Xu, R.-H.
Affiliations
  • National Cancer Center Hospital (JP)
  • Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
  • Henan Cancer Hospital (CN)
  • Sir Run Run Shaw Hospital (CN)
  • First Affiliated Hospital Zhejiang University (CN)
  • Shanghai Jiao Tong University (CN)
  • Asan Medical Center (KR)
  • Cabrini Hospital (AU)
  • Providence Portland Medical Center (US)
  • Liaoning Cancer Hospital & Institute (CN)
  • InventisBio Co., Ltd. (China) (CN)
  • Sun Yat-sen University (CN)
Corresponding author
Xu, Rui-Hua
Venue
British Journal of Cancer
Published
2025-12-04
Volume
134
Issue
3
Pages
457-462
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4416976247
Cited by
5
References
20
Citations by year
2026: 5
FWCI
2.06
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, treatment-related adverse events, anticancer activity, drug safety
MeSH terms
Progression-Free Survival, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41416-025-03286-w
The paper
Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., Zhang, J., Xiang, Z., Wang, W., Shi, Z., Zhang, L., Wang, Y., & Xu, R.-H. (2026). Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-025-03286-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.